- 1 Title Page
- 2

3	The association of ethnicity and oncologic outcomes for oral cavity squamous cell
4	carcinoma (OSCC)
5	Kiana Mahboubi ³ , Steven C. Nakoneshny ² , Khara Sauro ^{1,2,3,4,5,6} , Samuel Roberts ^{3,7} , Rob
6	Hart ^{2,3,5} , T Wayne Matthews ^{2,3,6} , Joseph Dort ^{1,2,3,5,6} , Shamir P Chandarana ^{2,3,5,6}
7	
8	¹ Department of Community Health Sciences, Cumming School of Medicine, University of
9	Calgary, Calgary, Alberta, Canada
10	² Ohlson Research Initiative, Arnie Charbonneau Cancer Institute, Cumming School of
11	Medicine, University of Calgary, Calgary, Alberta, Canada
12	³ Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Cumming
13	School of Medicine, University of Calgary, Alberta, Canada
14	⁴ O'Brien Institute of Public Health, Cumming School of Medicine, University of Calgary,
15	Calgary, Alberta, Canada
16	⁵ Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary,
17	Alberta, Canada
18	⁶ Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of
19	Calgary, Calgary, Alberta, Canada
20	⁷ School of Medicine and Public Health, University of Newcastle, Newcastle, Australia
21	
22	

24	Key Words:
25	South Asian; ethnicity; betel nut; oral squamous cell carcinoma (OSCC); oral cancer;
26	head and neck cancer
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

47 Abstract

Objective: To compare oncologic outcomes of South Asian (SA) patients treated at a
regional cancer centre in Canada, for oral squamous cell carcinoma (OSCC), to the
general population.

51 Methods: Adult patients who underwent primary surgical resection of OSCC +/adjuvant treatment between 2009 and 2022 (N=697) were included. SA patients were 52 53 identified using a validated method and compared to non-SA patients. Baseline 54 characteristics, including betel nut consumption, were compared, and disease-specific survival (DSS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier 55 56 methods, with median follow-up time of 36.4 months [SD 31.02]. Cox proportional 57 hazard regression models adjusted for potential confounders. A p-value < 0.05 was considered statistically significant. 58

Results: SA patients (9% of cohort, n = 64) were significantly younger and had lower rates of smoking and alcohol consumption compared to non-SA patients. There were no differences in tumor characteristics or the use of adjuvant radiation. SA patients had a two-fold higher risk of recurrence and significantly worse disease-specific survival, even after adjusting for stage and high-risk features [RFS: HR 2.01(1.28 - 3.14), DSS: HR 1.79(1.12 - 2.88)]. The consumption of betel nut was not associated with outcomes.

Conclusion: To our knowledge, this study is the first to compare the oncological
outcomes of SA patients with OSCC to non-SA patients. SA patients had significantly
worse outcomes, even after controlling for known predictors of recurrence and diseasespecific survival. These findings can inform personalized treatment decisions and

69 influence public health policies when managing patients with different ethnic

70 backgrounds.

71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			

92 Introduction

Head and neck cancer is the sixth most common cancer worldwide and is the 93 most common neoplasm in South Asia (1). Oral cavity cancers account for 30% of all 94 95 head and neck cancers and 90% of these are oral squamous cell carcinomas (OSCCs) (2,3). These cancers include tumours of the floor of the mouth, anterior tongue, alveolar 96 97 ridge, retromolar trigone, the hard palate, and the buccal mucosa. According to the World Health Organization, of the 267,000 newly diagnosed OSCCs worldwide, close to 98 40% occurred in South Asia (India, Pakistan, Bangladesh, and Sri Lanka). Furthermore, 99 100 oral cancer incidence and mortality rates in South Asia are almost twice those of global 101 rates (4).

102 There are a variety of factors that are known to contribute to the development of 103 OSCCs including the consumption of tobacco and alcohol, dental trauma, and human 104 papilloma virus (5). The predominance of OSCCs in South Asia is often attributed to the use of betel nut (6), which can be consumed in a variety of ways but is most often dried 105 and ground into a powder and wrapped in a package known as betel guid or pan, 106 107 comprised of a mixture of slaked lime, flavouring, and tobacco. Its use is influenced by 108 social acceptability, religious beliefs, and stimulant properties. Betel guid is often stored 109 inside the cheek for hours similar to chewing tobacco. The slaked lime, most often used 110 in India, is particularly problematic as it causes oxidative DNA damage and local 111 mucosal abrasion creating deeper exposure to the carcinogenic components (7).

112 Although there have been improvements in the quality of life of patients with 113 OSCC, both the disease itself as well as its treatment remain morbid with a 5-year

114 overall survival rate of 50 to 60% (8). Current treatments include surgical resection, radiotherapy, chemotherapy, or a combination of these modalities. The primary 115 116 treatment for early-stage (stage I and II) and advanced-stage (stage III and IV) OSCC is 117 surgical resection of the tumor (9). Previous North American studies have looked at the 118 differences in head and neck cancer disease outcomes according to ethnicity, showing 119 large disparity in mortality rates among African American versus white patients in the United States (10-12). These differences have been attributed to a combination of 120 121 tumour stage at time of presentation, access to healthcare, and exposure to 122 carcinogens. Nichols et al., reported that even after controlling for tumour stage at time 123 of presentation, African American patients had poorer outcomes, suggesting other 124 intrinsic and extrinsic factors such as genetics and socioeconomic status influence 125 survival in OSCC (13). Arbes et al., accounted for socioeconomic status, which resulted in elimination of the survival disadvantage observed among black patients (14). To 126 127 date, however, there has been little research that compares oncological outcomes of 128 patients of South Asian (SA) ethnicity with OSCCs compared to other ethnicities. 129 Our regional cancer centre, based in Calgary, Alberta, Canada, treats a high 130 volume of OSCC, in patients with diverse ethnic backgrounds. SA patients represent a significant proportion of patients treated. Given the increased incidence and mortality 131 rates of patients with OSCC in India, the objective of this study was to characterize 132 133 oncological outcomes among patients of SA ethnicity within our centre and compare

these outcomes to patients with OSCC who are not of SA ethnicity.

135

134

137 Methods and Material

138 Patient Selection

Adult patients (age 18 or older) that underwent curative intent primary surgical 139 140 resection of OSCC at a regional cancer centre were included in the cohort. The set up 141 of this study is that of a regional cancer centre where all head and neck cancers are 142 managed by a multidisciplinary team with expert training and extensive experience. Patient data (n=697) was prospectively collected, and included all patients treated 143 144 between 2009 to 2022. Patients with recurrent OSCC, a second primary malignancy, a 145 synchronous primary malignancy, or who did not receive surgery as a primary treatment 146 modality were excluded (Fig 1). Variables collected included: patient demographics, risk 147 factors (ethnicity, age, gender, smoking and alcohol status, betel nut use), pathologic 148 data (AJCC 8th edition TNM staging (15) including presence of extranodal extension 149 [ENE], lymphovascular invasion [LVI], perineural invasion [PNI]), and treatment 150 (adjuvant radiation and/or chemotherapy). 151 Patients of SA descent were identified using a multistep approach. First, a 152 previously constructed and validated SA surname list (16) was used to assign SA 153 ethnicity to the patient population. The validated SA surname list was then linked with the patient database to generate a SA patient list. In addition, to ensure the accuracy of 154 155 the cohort of SA patients, the final study cohort was manually entered into a surname's

156 origin website (17). This list was reviewed by two researchers with SA/middle eastern

157 backgrounds to generate a final list of SA patients. This method has been used

successfully to identify ethnic groups in other studies (18, 19).

159 Statistical Analysis

We interrogated a prospectively collected database of all patients treated for OSCC at the Calgary regional cancer centre. Patient factors, tumor factors, treatment factors and outcomes were analyzed and compared between the SA and non-SA groups.

164 Categorical outcomes were compared between groups using chi-square and 165 continuous outcomes were compared using Student's t-test. Primary outcomes were recurrence-free survival (RFS) and disease specific survival (DSS). RFS was defined as 166 167 time from surgery to time of last follow-up or local/regional/distant recurrence, whichever 168 came first. DSS was defined as time from surgery to time of last follow-up or death 169 related to OSCC. Difference in RFS and DSS between patients of SA ethnicity and 170 those of non-SA ethnicity were determined by comparing the time-to-event (Kaplan-171 Meier survival curves) using a log-rank test statistic. These were censored at 3 years of follow-up. Time-to-event outcomes were then adjusted for variables that potentially 172 173 modified or confounded the relationship between the outcome and exposure (social 174 habits, stage, high risk features on surgical pathology, type of adjuvant treatment) using 175 Cox proportional hazards (PH) regression models. These variables were, in part, based 176 on clinical relevance, having been shown in the literature to potentially modify the 177 oncologic outcomes (20-24). Variables that had a p-value of <0.20 in the univariate model were included in the multivariable model. Stepwise selection methods were used 178 179 to develop the final models. A p-value < 0.05 was considered statistically significant. 180 Owing to the prospective and rigorous nature of the data collection, missing data was 181 infrequently seen; when missing data was encountered, it was excluded from analysis. 182 Betel nut consumption was not prospectively collected, but due to the published

183	association between consumption and carcinogenesis, a chart review was performed,
184	and where possible, betel nut consumption was collected. A sub-analysis of only
185	patients of SA ethnicity was performed to look for association between betel nut
186	consumption and oncologic outcome (DSS and RFS), by comparing the time-to-event
187	(Kaplan-Meier survival curves) of those that did and did not consume betel nut, using a
188	log-rank test statistic.
189	Statistical Analysis was performed using Stata, version 14 (25). The study was
190	approved by the University of Calgary Conjoint Health Research Ethics Board.
191	
192	
193	
194	
195	
196	
197	
198	
199	
200	
201	
202	
203	
204	
205	Results

206 Using the previously described approach for selecting SA patients, we identified 207 64 SA patients and 632 non-SA patients, which served as the comparison group. We 208 were unable to classify 1 patient as either SA or non-SA (Figure 1). Of the 697 patients 209 that were included, 9% (n=64) were of SA ethnicity. Table 1 describes the cohort by 210 patient and tumour characteristics stratified by ethnicity. The median follow-up time was 211 36.4 months (SD=31.02). SA patients were significantly younger and were less likely to smoke or drink. There were no differences in tumor pathologic characteristics (T-stage, 212 213 N-stage, ENE, LVI, PNI), nor in the use of adjuvant radiation between the SA and non-214 SA patients.

215 Recurrence free survival

216 Univariate Kaplan-Meier analysis revealed that patients of SA ethnicity had 217 worse RFS [HR=2.35 (1.51–3.65)] than those of non-SA ethnicity (Figure 2A). RFS for 218 SA patients at 3-year follow up was 52%, compared to 76% in the non-SA group (p<0.01). Pathologic characteristics were significantly associated with worsened RFS, 219 220 regardless of ethnicity: advanced T- stage [HR=2.17 (1.55–3.04)], node positivity [HR= 2.98 (1.99–4.45)], presence of ENE [HR=5.39 (3.57–8.14)], advanced clinical stage 221 222 [HR = 5.14 (2.82–9.36)], presence of LVI [HR = 2.93 (2.00–4.29)], and presence of PNI [HR = 1.78 (1.24–2.55)] (Figure 2A). 223 After adjusting for the above-mentioned covariates on multivariable analysis, SA 224 225 ethnicity [HR=2.01 (1.28 - 3.14)], advanced T-stage [HR =1.46 (1.02 - 2.10)], nodal

226 positivity [HR=2.65 (1.77 - 3.99)], and presence of ENE [HR=4.32 (2.75 - 6.78)] were all

associated with worsened RFS (Table 2).

228 Disease-specific survival

229 On univariate Kaplan-Meier analysis, SA ethnicity was associated with worsened disease-specific survival [HR=2.14 (1.34-3.42)]. DSS for SA patients at 3-year follow up 230 231 was 59%, compared to 77% in the non-SA group (p<0.01). Other negative prognostic 232 features included: advanced T- stage [HR=2.37 (1.66-3.36)], nodal positivity [HR=3.70 (2.38–5.74)], presence of ENE [HR=8.04 (5.24–12.35], advanced clinical stage [HR = 233 7.67 (3.73–15.78)], presence of LVI [HR = 3.11 (2.11–4.57)], and presence of PNI [HR 234 = 2.20 (1.53-3.18)] (Figure 2B). 235 After adjusting for the above-mentioned covariates on multivariable analysis, SA 236

ethnicity [HR=1.79 (1.12–2.88)], advanced T-stage [HR = 1.64 (1.10–2.43)], node

238 positivity [HR=3.97 (2.44–6.45)], and presence of ENE [HR=16.40 (9.00–29.91)]

239 predicted worsened DSS (Table 3).

240 Pattern of failure in those that recurred

Among the 193 patients that developed a recurrence, 86% of patients of SA ethnicity recurred either locally or regionally, compared to the 87% in the patients of non-SA ethnicity. Conversely, 14% of patients of SA ethnicity and 13% of patients of non-SA ethnicity had distant recurrence. The difference in pattern of failure was not significant.

246 Betel nut use in SA patients

Chart review of the 64 SA patients revealed that 23 used betel nut, 28 did not use betel nut, and 13 did not have betel nut use reported. Univariate analysis of just the SA patients did not predict a difference in RFS or DSS between those who used betel nut and those who did not (Figure 3).

251 Discussion

252 This study demonstrated that patients of SA ethnicity had significantly worse survival outcomes and were twice as likely to recur compared to non-SA patients even 253 254 after accounting for other known factors contributing to poor oncological outcomes. The 255 SA community is one of the largest and fastest growing minority groups in Canada 256 based on the 2021 census (26). Considering the migration patterns within the South 257 Asian community and their correlation with the prevalence of OSCC, it's important to 258 acknowledge the potential impact on health trends in Canada. Understanding these 259 patterns, can help promote public health initiatives and ensure that the unique needs of 260 the South Asian population are met, fostering a more inclusive and supportive 261 environment. Studies conducted in Malaysia (27,28), UK (29), Australia (30), and South 262 Africa (31) indicate that individuals of SA heritage are at higher risk of oral cancer than 263 the non-SA population in those countries. A study in British Columbia, which has one of the highest South Asian immigrant populations in Canada, demonstrated a relative risk 264 265 of developing OSCC of 1.33 and 1.66 for South Asian men and women, respectively, as 266 compared with the non-SA population (32). Anecdotally, the senior authors at our centre, who treat high volumes of OSCC, felt that year over year, SA patients 267 268 represented a disproportionately larger ethnicity group than other ethnicities, and were 269 recurring more frequently. The decision to formally evaluate outcomes based on SA 270 ethnicity was therefore born out of concern for a potentially at-risk population, in hopes 271 to validate the need for a more tailored approach to treating this group of patients, as 272 well as to build awareness and inform public health policy.

This study uniquely evaluates differences in oncological outcomes of patients of SA ethnicity affected by OSCCs compared to patients of non-SA ethnicity. This results

275 suggest that, in Canada, SA ethnicity is an independent predictor of recurrence-free and worse disease-specific survival, when compared to non-SA patients. The study is 276 277 conducted within the framework of a regional cancer center, where a dedicated 278 multidisciplinary team, possessing expert training and extensive experience, oversees 279 the management of all head and neck cancers. This setup intentionally minimizes bias 280 for selection for more complicated cases. Stage of diagnosis is regarded as one of the 281 most important predictors of oral cancer survival with a significantly improved 5-year 282 survival rate for early-stage disease (71.4%) than for late-stage disease (21.8%) (33). In 283 this study, when comparing baseline characteristics of SA and non-SA patients, 284 oncological parameters such as T-Stage, N-stage, ENE, LVI and PNI were similar which 285 suggests they were not the primary drivers of differences in recurrence and worse 286 survival in SA patients. This association was also found in multivariable analysis. The similarity in these variables between groups also infers that there are no discrepancies 287 288 in access to care, which would likely lead to a delayed presentation, with more 289 advanced disease at time of presentation. Although, the initial presenting burden of 290 disease is an imperfect tool to estimate access to care, in a universal health care 291 system, issues such as treatment delay, is relatively uniform across all sub-populations. 292 Interestingly, features that are typically protective against developing OSCC such as 293 younger age and non-smoking status were more common in SA patients. Despite this, 294 being SA resulted in a two-fold increase in recurrence and decrease in OSCC survival. 295 As expected, patients with advanced T stage (T3/4), nodal disease and ENE had both 296 worsened DSS and RFS, validating that the patient cohort in this study is representative 297 of the greater head and neck cancer population. Disease stage at time of diagnosis has

been previously identified as a causative factor in poorer oncological outcome in
minority groups (34). In this study, even after controlling for disease stage, SA ethnicity
remained as an independent factor in predicting survival and recurrence.

301 Several factors potentially contribute to the poorer outcomes of OSCC in SA 302 patients. One of the major factors is thought to be the use of betel nut in the SA culture, 303 which is commonly consumed in the form of betel guid. Although the added tobacco plays a significant role in the development of OSCCs, studies have suggested that betel 304 products, which contain arecoline and 3-(methylnitrosamino) propionitrile, may have an 305 306 independent carcinogenic effect (35) resulting in malignant transformation of oral 307 submucosal fibrosis (OSMF). The potential for malignant transformation resulting in 308 OSCC has been reported to be as high as 7 to 13% (36). Although the exact 309 mechanism is not well understood, betel nut is thought to induce *c-jun* proto-oncogene 310 expression in human mucosal fibroblasts (37). The fibrosis itself can result in decreased 311 vascularity and hypoxia thus mediating mutated cell divisions (38). This study did not 312 find any differences on either recurrence or survival among patients of SA ethnicity 313 based on betel nut use; however, given that betel nut consumption was not consistently 314 reported in patient charts, further investigation with larger numbers and more consistent 315 reporting is required to verify this finding.

Pattern of recurrence describes whether a patient recurs locally, regionally, or at a distant site. Given that betel nut is often stored inside the cheek for prolonged periods of time, one would expect SA patients to recur locoregionally if betel nut use is the causative factor. In our study population, the majority of recurrences in the SA population were local/regional however, the proportion of patients that recurred

locoregionally was not significantly different between SA and non-SA patients. This
 suggests that regardless of the causative agent for OSCC, recurrences are more likely
 to manifest as local/regional rather than distant disease.

324 A strength of this study relies on the rigorous, prospective collection of data 325 including patient related factors, tumor factors, treatment factors and oncologic 326 outcomes. A limitation is the relatively small sample size within the SA cohort. A larger 327 multicentre study could yield more definitive results on this issue. Given the absence of 328 race or ethnicity information in many databases used in health research, surnames are 329 frequently employed as a proxy when investigating healthcare patterns within ethnic 330 populations. Despite this, a limitation arises in potentially excluding individuals of South 331 Asian background who may have undergone name changes. However, it should be 332 noted that in Canada, according to the 2021 census, 76% of South Asians were recent immigrants born outside of Canada (26), and therefore, the likelihood of experiencing a 333 334 name change is low. This study also did not differentiate between SA immigrants and 335 Canadian born people of SA ethnicity (first and subsequent generations) which hinders 336 the ability to distinguish between the role of environment versus inheritance on the 337 findings. There are important factors related to immigration status that may mediate the 338 findings of this study, some of which include betel nut use, environmental factors and 339 genetic factors. Although, there is no specific data on the use of betel nut in Canada, 340 UK and Australian data shows that it is commonly used among first generation 341 immigrants and its use is reduced in subsequent generations (39). However, in younger 342 generations, the form of consumption is tilting towards ingestion which may result in 343 higher rates of esophageal cancers (39). As such, a more granular study on time since

344 immigration and mode of betel nut use would be informative. In addition to environmental factors, genetics can also play a role in the poor outcomes observed in 345 346 South Asian patients with OSCC. However, no specific genes have been identified as 347 predisposing factors for OSCC in the SA population and the hereditary factors that 348 contribute to the disease are largely unknown. While most cases of OSCC occur 349 sporadically, certain families with a high preponderance of the disease have been found to carry oncogenes such as VAV2 and IQGAP1 with an autosomal dominance 350 351 penetrance (40). Moreover, with the emergence of precision medicine, there has been a 352 growing interest in identifying diagnostic and prognostic biomarkers for OSCC. One 353 such biomarker is microRNA (miRNA), a large group of small single-stranded non-354 coding endogenous RNAs that play a role in post-transcriptional gene regulation. 355 Upregulation of miRNAs is thought to contribute to OSCC resistance to chemoradiation 356 and recurrence (41). Our centre is involved in banking the tumors of all consecutive 357 OSCC patients and intends to explore the potential molecular basis of poor OSCC 358 outcomes in the SA population.

The findings of this study reveal that patients with SA ethnicity experience significantly poorer outcomes compared to the non-SA cohort, even after accounting for other predictors of poor outcome. To gain a more comprehensive understanding of the intricate interplay between ethnicity, environmental exposure, and genetic predisposition in OSCC outcomes, further research is imperative. Such research could pave the way for personalized treatment decisions and patient counseling, as well as the formulation of public health policies that serve to assist vulnerable and at-risk populations.

366

367	Conclusion						
368	Patients of SA ethnicity had worse outcomes (higher risk of recurrence and						
369	worsened survival) than patients with non-SA ethnicity, even after controlling for other						
370	known predictors of poor outcome in OSCC. These finding can inform more						
371	individualized treatment decision making and impact public health policy when serving						
372	heterogeneous patient populations.						
373							
374							
375							
376							
377							
378							
379							
380							
381							
382							
383							
384							
385							
386							
387							
388							
389							

390 **References**

- Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. *CA: A Cancer Journal for Clinicians*. 2005;55(2):74-108.
- Moore S, Johnson N, Pierce A, Wilson D. The epidemiology of tongue cancer: a
 review of global incidence. *Oral Diseases*. 2008;6(2):75-84.
- Rapidis A. Head and Neck Cancer: Multimodality Management. In: Bernier J,
 editor. Multidisciplinary management of oral cavity and maxillary sinus cancers.
 New York, NY: Springer Science 1 Business Media, LLC; 2011.
- Gupta B, Ariyawardana A, Johnson NW. Oral cancer in India continues in
 epidemic proportions: evidence base and policy initiatives. *Int Dent J*. 2013
 Jan;63(1):12-25.
- 401 5. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. *Oral* 402 *Oncology*. 2009;45(4-5):309-316.
- 403 6. IARC monographs on the evaluation of the carcinogenic risk of chemicals to
- 404 humans. Vol. 37. Tobacco habits other than smoking; Betel-quid and Betel-nut
- 405 chewing; and some related nitrosamines. *Food and Chemical Toxicology*.

406 1986;24(8):885-886.

- Chen PH, Mahmood Q, Mariottini GL. Betel quid and oral cancer: a review with
 emphasis on its prevalence, etiology, and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2016;34(4):249-261.
- 8. Epstein JB, Thariat J, Bensadoun RJ, et al. Oral squamous cell carcinoma: early
 detection and intervention. *Can J Otolaryngol Head Neck Surg*. 2011;39(4):275281.

- 413 9. National Comprehensive Cancer Network. Head and neck cancers (version
 414 3.2021). Accessed May 4, 2023.
- 415 <u>https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf</u>
- 416 10. Yu AJ, Choi JS, Swanson MS, et al. Association of Race/Ethnicity, Stage, and
- 417 Survival in Oral Cavity Squamous Cell Carcinoma: A SEER Study. *OTO Open*.
 418 2019;3(4).
- 419 11. Goodwin WJ, Thomas GR, Parker DF, et al. Unequal burden of head and neck
 420 cancer in the United States. *Head Neck*. 2008;30:358-371.
- 421 12. Molina MA, Cheung MC, Perez EA, et al. African American and poor patients
- have a dramatically worse prognosis for head and neck cancer: an examination
 of 20,915 patients. *Cancer*. 2008;113:2797-2806.
- 424 13. Nichols AC, Bhattacharyya N. Racial differences in stage and survival in head
 425 and neck squamous cell carcinoma. *Laryngoscope*. 2007;117:770-775.
- 426 14. Arbes SJ Jr, Olshan AF, Caplan DJ, et al. Factors contributing to the poorer
- 427 survival of black Americans diagnosed with oral cancer (United States). *Cancer*
- 428 *Causes Control* 1999;10:513–523.
- 429 15. AJCC. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
- 430 16. Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify
- 431 South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a
- 432 validation study. *BMC Medical Research Methodology*. 2010;10(1).
- 433 17. Surnames Meanings, Origins & Distribution Maps. Forebears.io. Published 2012.
- 434 <u>https://forebears.io/surnames</u>
- 435 18. Auluck A, Hislop G, Bajdik C, Hay J, Bottorff JL, Zhang L, Rosin MP. Gender-

436	and ethnicity-specific survival trends of oral cavity and oropharyngeal cancers in
437	British Columbia. Cancer Causes Control. 2012;23(12):1899-1909.
438	19. Hislop GT, Bajdik CD, Regier MD, Barroetavena MC. Ethnic differences in
439	survival for female cancers of the breast, cervix and colorectum in British
440	Columbia, Canada. Asian Pac J Cancer Prev. 2007;8(2):209-214.
441	20. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced
442	head and neck cancers: a comparative analysis of concurrent postoperative
443	radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#
444	9501). Head Neck. 2005;27(10):843-850.
445	21. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable
446	head and neck tumors based on RTOG #85-03 and #88-24: targets for
447	postoperative radiochemotherapy?. <i>Head Neck</i> . 1998;20(7):588-594.
448	22. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and
449	time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int
450	J Radiat Oncol Biol Phys. 2001;51(3):571-578.
451	23. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in
452	surgery and postoperative radiation therapy for squamous carcinoma of the head
453	and neck. <i>Head Neck</i> . 2002;24(2):115-126.
454	24. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in
455	squamous cell carcinoma of the oral cavity: the importance of the overall
456	treatment time. Int J Radiat Oncol Biol Phys. 2003;57(3):693-700.
457	25. StataCorp. 2023. Stata Statistical Software: Release 18. College Station, TX:
458	StataCorp LLC.

459	26. Government of Canada, Statistics Canada. Census Profile, 2021 Census -
460	Canada [Country] and Canada [Country]. Statcan.gc.ca. Published 2021.
461	Accessed February 8, 2023. https://www12.statcan.gc.ca/census-
462	recensement/2016/dp-
463	pd/prof/details/page.cfm?Lang=E&Geo1=PR&Code1=01&Geo2=PR&Code2=01
464	&Data=Count&SearchText=Canada&SearchType=Begins&SearchPR=01&B1=Et
465	hnic%20origin&TABID=1
466	27. Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral
467	mucosal lesions in Malaysia. Community Dentistry and Oral Epidemiology.
468	1997;25(5):377-383.
469	28. Ali TBT, Jalaliuddin RLR, Razak IA, Zain RB. Prevalence of Oral Precancerous
470	and Cancerous Lesions in Elderly Malaysians. Asia Pacific Journal of Public
471	Health. 1997;9(1):24-27.
472	29. Warnakulasuriya S. Betel nut use following migration and its consequences.
473	Addiction Biology. 2002;7(1):127-132.
474	30. Petti S. Lifestyle risk factors for oral cancer. Oral Oncology. 2009;45(4-5):340-
475	350.
476	31. Van Wyk CW, Stander I, Padayachee A, Grobler-Rabie AF. The betel nut
477	chewing habit and oral squamous cell carcinoma in South African Indians. A
478	retrospective study. South African Medical Journal 1993;83(6):425-429.
479	32. Rock LM, Datta M, Laronde DM, Carraro A, Korbelik J, Harrison A, Guillaud M.
480	Conducting community oral cancer screening among South Asians in British
481	Columbia. <i>J Cancer Educ</i> . 2012;27(2):354-358.

- 33. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and
 prognosis for head and neck cancer in the United States: A site-specific analysis
 of the SEER database. *International Journal of Cancer*. 2004;114(5):806-816.
- 485 34. Shiboski CH, Schmidt BL, Jordan RCK. Racial disparity in stage at diagnosis and
- 486 survival among adults with oral cancer in the US. *Community Dentistry and Oral*487 *Epidemiology*. 2007;35(3):233-240.
- 488 35. Senevirathna K, Pradeep R, Jayasinghe YA, et al. Carcinogenic Effects of Betel
- 489 Nut and Its Metabolites: A Review of the Experimental Evidence. *Clinics and*490 *Practice*. 2023;13(2):326-346.
- 491 36. Phulari RGS, Dave EJ. A systematic review on the mechanisms of malignant
- 492 transformation of oral submucous fibrosis. *Eur J Cancer Prev*. 2020;29(5):470493 473.
- 494 37. Warnakulasuriya S. Betel nut use: an independent risk factor for oral
 495 cancer. *BMJ*. 2002;324(7341):799-800.
- 496 38. Veeravarmal V, Austin R, Siddavaram N, Thiruneelakandan S, Nassar MHM.
- 497 Caspase-3 expression in normal oral epithelium, oral submucous fibrosis and
- 498 oral squamous cell carcinoma. *Journal of Oral and Maxillofacial Pathology*.
- 499 2016;20(3):445.
- 39. Auluck A, Hislop G, Poh C, Zhang L, Rosin MP. Betel nut and betel quid chewing
 among South Asian immigrants to Western countries and its implications for oral
 cancer screening. *Rural Remote Health*. 2009;9(2):1118.
- 40. Huang Y, Zhao J, Mao G, et al. Identification of novel genetic variants
- 504 predisposing to familial oral squamous cell carcinomas. *Cell Discovery*.

505 2019;5(1).

- 506 41. Dioguardi M, Spirito F, Sovereto D, et al. The Prognostic Role of miR-31 in Head
- 507 and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis with
- 508 Trial Sequential Analysis. *Int J Environ Res Public Health*. 2022;19(9):5334.

Tables

Table 1. Patient Demographics

Characteristic			Non-South		
		Total	Asian	South Asian	p-value
		n=696	n=632	n=64	
Gender					ns
	Female	265	244	21	
	Male	431	388	43	
Age					0.0194
	Mean [SD]	62.4 [13.34]	62.8 [13.24]	58.0 [13.72]	
	Range	23.6 - 96.3	23.6 - 96.3	25.8 - 79.3	
Smoking History					<0.0001^
	Never Smoked	191	153	38	
	Ex-smoker	258	244	14	
(Current Smoker	227	216	10	
	Not Stated	21	19	2	
Betel Nut Usage					N/A
-	Yes	23	N/A	23	1
	No	28	N/A	28	
	Not Stated	13	N/A	13	
Drinking History		10		10	<0.0001^
	Never Drinker	155	121	34	
	Ex-drinker	70	66	<u>л</u>	
(Current Drinker	70 411	395	- 16	
	Not Stated	60	50	10	
Pathologic T stage	Not Stated	00	50	10	nc
ratiologic i stage	T0/Tis	31	29	2	115
	T1	234	25	17	
	T2	169	149	20	
	T2	83	76	7	
	T4	171	153	18	
	Тх	8	8	0	

Pathologic N stage				ns
NO	268	245	23	
N1	70	64	6	
N2	138	121	17	
N3	29	25	4	
Nx	186	177	14	
Pathologic Clinical Stage				ns
Stage 0	4	3	1	
Stage I	74	70	4	
Stage II	87	77	10	
Stage III	80	73	7	
Stage IV	260	232	28	
Not Stated	191	177	14	
Extracapsular Spread				ns
ECS not present	146	131	15	
ECS present	93	81	12	
N/A (eg N0 neck)	457	420	37	
Lymphyascular Invasion				ns
Absent	500	456	44	_
Present	112	102	10	
Not Stated	84	74	10	
Perineural Invasion				ns
Absent	403	363	40	110
Present	202	185	17	
Not Stated	91	84	7	
Treatment	51	01		ns
Surgery Alone	427	389	38	115
Surgery + Radiation	180	166	14	
Surgery + Chemoradiation	200	77	12	
Surgery + Chemoraulation	09	//	12	

^ Wilcoxon rank-sum test; * Fisher's exact test; ns= not significant

 Table 2: Cox Regression Analysis for Recurrence Free Survival

	Univariate An	alysis	Multivariable Analysis		
Variable	Hazard ratio [95% CI]	p-value	Hazard ratio [95% CI]	p-value	
Ethnicity, non-SA vs SA	2.35 [1.51 - 3.65]	<0.0001	2.01 [1.28 - 3.14]	0.002	
Pathologic T Classification, pT0- pT2 vs pT3-pT4	2.17 [1.55 - 3.04]	<0.0001	1.46 [1.02 - 2.10]	0.04	
Pathologic Node Positivity, pN0 vs pN+	4.81 [3.08 - 7.51]	<0.0001	-	-	
Clinical Stage, I/II vs III/IV	5.14 [2.82 - 9.36]	<0.0001	-	-	
Lymphovascular Invasion, no vs yes	2.93 [2.00 - 4.29]	<0.0001	-	-	
Perineural Invasion, no vs yes	1.78 [1.24 - 2.55]	0.002	-	-	
Extracapsular Spread (ref: NO)					
N+, ECS–	2.98 [1.99 - 4.45]	<0.0001	2.65 [1.77 - 3.99]	<0.0001	
N+, ECS+	5.39 [3.57 - 8.14]	<0.0001	4.32 [2.75 - 6.78]	<0.0001	
Treatment Modality (ref: Surgery					
Alone)					
Surgery + Radiation	2.30 [1.57 - 3.36]	<0.0001	-	-	
Surgery + Chemoradiation	2.84 [1.83 - 4.34]	<0.0001	_	_	

	Univariate Analysis		Multivariable Analysis			
Variable	Hazard ratio [95% CI]	p-value	Hazard ratio [95% CI]	p-value		
Ethnicity, non-SA vs SA	2.14 [1.34 - 3.42]	0.001	1.79 [1.12 - 2.88]	0.016		
Pathologic T Classification, pT0- pT2 vs pT3-pT4	2.37 [1.66 - 3.36]	<0.0001	1.64 [1.10 - 2.43]	0.015		
Pathologic Node Positivity, pN0 vs pN+	6.10 [3.75 - 9.92]	<0.0001	-	-		
Clinical Stage, I/II vs III/IV	7.67 [3.73 - 15.78]	<0.0001	-	-		
Lymphvascular Invasion, no vs yes	3.11 [2.11 - 4.57]	<0.0001	-	-		
Perineural Invasion, no vs yes	2.20 [1.53 - 3.18]	<0.0001	-	_		
Bone Invasion, no vs yes	1.80 [1.11 - 2.92]	0.017	_	_		
Extracapsular Spread (ref: NO)						
N+, ECS–	3.70 [2.38 - 5.74]	<0.0001	3.97 [2.44 - 6.45]	<0.0001		
N+, ECS+	8.04 [5.24 - 12.35]	<0.0001	16.40 [9.00 - 29.91]	<0.0001		
Treatment Modality (ref: Surgery						
Alone)						
Surgery + Radiation	2.28 [1.53 - 3.41]	<0.0001	0.85 [0.53 - 1.36]	ns		
Surgery + Chemoradiation	3.14 [2.00 - 4.94]	<0.0001	0.27 [0.14 - 0.53]	<0.0001		
ns= not significant						